Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
N4 Pharma ( (GB:N4P) ) just unveiled an update.
N4 Pharma has announced its audited results for the year ending December 2024, highlighting significant operational and financial achievements. The company has made strides in developing its Nuvec® platform, evidenced by successful in vitro and in vivo studies, new patent filings, and collaborations that demonstrate the platform’s potential in targeted drug delivery. Financially, the company reported increased revenue and reduced operating losses, supported by successful fundraising efforts. The strategic focus remains on enhancing the Nuvec® platform to secure licensing agreements and unlock its commercial potential, with a strong leadership team driving this agenda.
More about N4 Pharma
N4 Pharma plc is a UK-based biotechnology company focused on developing Nuvec®, a proprietary gene delivery system aimed at advancing therapies for cancer and other diseases. The company is dedicated to creating RNA therapeutic products and forming commercial partnerships through its innovative platform.
Average Trading Volume: 1,709,957
Technical Sentiment Signal: Strong Sell
Current Market Cap: £7.24M
See more insights into N4P stock on TipRanks’ Stock Analysis page.